MedMira Inc. (MMIRF)

OTCMKTS · Delayed Price · Currency is USD
0.0133
0.00 (0.00%)
Feb 5, 2026, 4:00 PM EST
Market Cap36.06M -11.6%
Revenue (ttm)166.26K -34.6%
Net Income-2.88M
EPS-0.00
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,000
Average Volume18,391
Open0.0133
Previous Close0.0133
Day's Range0.0133 - 0.0133
52-Week Range0.0120 - 0.1000
Beta0.66
RSI44.43
Earnings DateApr 2, 2026

About MedMira

MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 52
Stock Exchange OTCMKTS
Ticker Symbol MMIRF
Full Company Profile

Financial Performance

In fiscal year 2025, MedMira's revenue was 240,509, a decrease of -41.70% compared to the previous year's 412,568. Losses were -4.52 million, 36.0% more than in 2024.

Financial numbers in CAD Financial Statements

News

MedMira (MMIRF) Reports Q1 Revenue Decline and Reduced Net Loss

MedMira (MMIRF) Reports Q1 Revenue Decline and Reduced Net Loss

6 weeks ago - GuruFocus

Medmira reports Q1 results

Get the latest on Medmira's Q1 financials: revenue, year-over-year performance, and improved net loss figures.

6 weeks ago - Seeking Alpha

MedMira Reports First Quarter Results FY2026

HALIFAX, NOVA SCOTIA / ACCESS Newswire / December 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2025. Corporate update In Q1 F...

6 weeks ago - Accesswire

MedMira Reports FY2025 Fourth Quarter and Year End Financial Results

HALIFAX, NOVA SCOTIA / ACCESS Newswire / November 28, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2025. Corporate update In ...

2 months ago - Accesswire

Health Canada Approves MedMira's Reveal(R) Rapid TP Test - Urgent New Tool In The Battle Against Syphilis

HALIFAX, NOVA SCOTIA / ACCESS Newswire / August 26, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received approval from Health Canada for its Reveal® TP (Syphilis) Antibody Tes...

6 months ago - Accesswire

MedMira Announces Launch of Clinical Trial for Its Multiplo(R) TP/HIV Self-Test in Canada

HALIFAX, NS / ACCESS Newswire / July 7, 2025 / MedMira Inc. (MedMira) (TSXV: MIR) and REACH Nexus are excited to announce a clinical trial has officially started earlier than anticipated to evaluate M...

7 months ago - Accesswire

MedMira Reports Second Quarter Results FY2025

HALIFAX, NS / ACCESS Newswire / June 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2025. Corporate update In Q3 FY2025, MedMir...

8 months ago - Accesswire

MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense

HALIFAX, NS / ACCESS Newswire / April 17, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as ...

10 months ago - Accesswire

Medmira reports Q2 results

11 months ago - Seeking Alpha

MedMira Reports Second Quarter Results FY2025

HALIFAX, NS / ACCESS Newswire / April 1, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2025. Corporate update In Q2 FY2025, MedMir...

11 months ago - Accesswire

MedMira Announces Partnership with MediGroup Physician Services in the United States

HALIFAX, NS / ACCESS Newswire / February 27, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today its partnership with MediGroup, a leader in the US health care industry since 1999. This new partn...

1 year ago - Accesswire

MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada

HALIFAX, NS / ACCESS Newswire / February 25, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today its exclusive distribution agreement with Trimedic Inc. for the Canadian market. This partnership ...

1 year ago - Accesswire

MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications

HALIFAX, NS / ACCESS Newswire / January 21, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clin...

1 year ago - Accesswire

MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications

MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clinical trials for new label claim applications of its...

1 year ago - Accesswire

MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use

HALIFAX, NS / ACCESSWIRE / January 14, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today the approval from Health Canada for its Reveal®Rapid G4 HIV-1/2 Test (Reveal®...

1 year ago - Accesswire

MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use

MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today the approval from Health Canada for its Reveal®Rapid G4 HIV-1/2 Test (Reveal® HIV test) for Point-of-Care (POC) use. The Re...

1 year ago - Accesswire

MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test

HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trial...

1 year ago - Accesswire

MedMira Reports First Quarter Results FY2025

HALIFAX, NS / ACCESSWIRE / December 30, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2024. Corporate update During Q1 FY2025, Med...

1 year ago - Accesswire

MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV

HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo® Rap...

1 year ago - Accesswire

MedMira Reports FY2024 Fourth Quarter and Year End Financial Results

HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. Corporate Update In December 2023,...

1 year ago - Accesswire

MedMira Announces the appointment of Vice President of Commercial Operations

MedMira Inc. continues its North-American expansion plan HALIFAX, NS / ACCESSWIRE / October 3, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) today announced the appointment of Nicole Crenshaw as Vic...

1 year ago - Accesswire

MedMira Reports Third Quarter Results FY2024

HALIFAX, NS / ACCESSWIRE / July 2, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2024. Corporate update In Q3 FY2024, MedMira focuse...

1 year ago - Accesswire

MedMira Announces the Hire of Vice President of Business Development

HALIFAX, NS / ACCESSWIRE / April 30, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the position of ...

1 year ago - Accesswire

MedMira Reports Second Quarter Results FY2024

HALIFAX, NS / ACCESSWIRE / April 1, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2024. Corporate update During Q2 FY2024, MedMira...

2 years ago - Accesswire

MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System

HALIFAX, NS / ACCESSWIRE / March 13, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of a Canadian patent patent (number 2,949,634) for its new innovative and quantitative test s...

2 years ago - Accesswire